Singapore startup Mesh Bio has raised $Three.5 million in a Collection A funding spherical led by East Ventures. Elev8, Seed Capitals and their different shareholders additionally participated within the spherical.
WHAT IS IT FOR?
In an announcement, the corporate mentioned it’ll use its recent funds to scale the rollout of its options, notably its flagship digital twin providing, in Hong Kong and Southeast Asia.
The World Well being Group revealed in 2019 that 76% of all deaths within the area had been attributed to non-communicable illnesses comparable to coronary heart illness and diabetes. Mesh Bio focuses on each Indonesia and the Philippines, the place power illnesses are mentioned to be extra prevalent and lethal. “Southeast Asia has numerous unmet healthcare wants and we purpose to successfully handle these gaps,” mentioned Dr. Andrew Wu, CEO and co-founder.
THE BIGGEST TREND
The newest funding increase comes three months after Mesh Bio obtained regulatory clearance from the Well being Sciences Authority of Singapore for HealthVector Diabetes. Software program as a digital twin-based medical system can predict a Three-year danger of creating power kidney illness in sufferers with kind 2 diabetes through the use of scientific information extracted from hospital EMRs.
The digital twin answer, which is an expanded providing of Mesh Bio’s DARA healthcare intelligence platform, is now being trialled at Singapore Normal Hospital, Tan Tock Seng Hospital and chosen polyclinics in Singapore.
The event of HealthVector Diabetes was first reported in October.